Metopimazine Biogaran

Metopimazine, the active ingredient in Metopimazine Biogaran, is a phenothiazine antiemetic presented as an oral tablet for oral use. It treats nausea and vomiting in adult patients. GNH USA supplies Metopimazine Biogaran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopimazine is a phenothiazine antiemetic that acts on dopamine pathways to control emesis. - Nausea: reduces the frequency and intensity of nausea episodes. - Vomiting: helps stop acute vomiting episodes. - Post‑operative nausea and vomiting (PONV): prevents or treats nausea and vomiting after surgery.

Metopimazine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Drowsiness: mild to moderate sedation. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: transient light‑headedness. - Blurred vision: temporary visual disturbances. - Weight gain: modest increase in appetite.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity or tremor. - Tardive dyskinesia: persistent involuntary movements. - Neuroleptic malignant syndrome: life‑threatening hyperthermia. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Agranulocytosis: severe reduction in white blood cells.

Before prescribing Metopimazine, clinicians should consider patient‑specific factors and monitor for potential risks. - Renal or hepatic impairment: adjust use and monitor function. - Elderly patients: start with the lowest effective dose. - Known hypersensitivity: avoid if allergic to phenothiazines. - Cardiovascular disease: watch for hypotension or arrhythmias. - Discontinuation: taper gradually to reduce withdrawal effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metopimazine can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - CNS depressants (e.g., opioids, benzodiazepines): additive sedation. - Antihypertensive agents: may cause excessive blood‑pressure lowering.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: increased anticholinergic burden. - QT‑prolonging medications: potential cardiac rhythm disturbances. - CYP2D6 inhibitors: may raise Metopimazine plasma levels. - Alcohol: enhances central nervous system depression. - Other antipsychotics: may increase extrapyramidal risk.